SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Heal with Confidence: Leading in Complex Patients

SYNERGY BP-DES was intentionally designed with a fast-absorbing polymer for early healing. The latest clinical data from EuroPCR continues to show low event rates with the SYNERGY BP-DES.

“If you believe that short DAPT is preferable, we now have very strong evidence to select the SYNERGY Stent.”

– Prof. Stefan James

SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT Cohort1,2

  • Randomized, single-blind trial evaluating the SYNERGY BP-DES and the REBEL™ BMS in patients 75 years or older with a short duration of DAPT
  • Over 50% of patients enrolled received a 1-month DAPT regimen – largely stable patients
  • Zero ST with SYNERGY BP-DES after patients stopped DAPT at 1-Month through 12-Months1*

Primary Endpoint: MACCE** at 12-months

Primary Endpoint: MACCE at 12-months

Safety Endpoints at 12-months

Safety Endpoints at 12-months
*In patients eligible for 1-month DAPT in this study. Please review the SYNERGY DFU for full instructions on DAPT.
**All-cause mortality, MI, stroke, ischemia-driven TLR
 
 

SYNTAX II Trial 2-Year Results3‡

  • Prospective, single-arm, multicenter, open-label trial of patients with de novo three-vessel CAD
  • The MACCE rate (primary endpoint) was significantly lower in SYNTAX II (13.2%) vs SYNTAX I (21.9%). (P=0.001)
  • SYNERGY BP-DES, physiological assessment, IVUS guidance, and contemporary PCI techniques demonstrated equivalent outcomes to CABG in patients with three-vessel disease. (MACCE rate of 13.2% PCI vs 15.1% CABG, P<0.001 for non-inferiority)

MACCE vs. Historical PCI - 2 Year Results

Primary Endpoint: MACCE vs. Historical PCI - 2 Year Results

MACCE PCI vs. Historical CABG - 2 Year Results

Exploratory Endpoint: MACCE PCI vs. Historical CABG - 2 Year Results
† Angiographically-detected.
 

SCAAR AMI Substudy 2-Year Results4‡

  • Evaluated SYNERGY BP-DES compared to all other new-generation DES in the SCAAR Registry in 36,292 patients with AMI at 2-Years
  • Lowest ST rate with SYNERGY BP-DES in AMI patients despite use in more complex patients and lesions

Definite Stent Thrombosis

Definite Stent Thrombosis

Restenosis

Restenosis
All other newer generation DES included the following stents: Resolute Integrity™, Resolute Onyx™, Xience Xpedition™, PROMUS Element Plus™, Promus PREMIER™, Orsiro™, Biomatrix™, and Ultimaster™. There were 4,889 SYNERGY BP-DES patients and 31,403 ‘other new-generation DES’ patients.
 

CONSISTENT CTO Study 12-Month Results5‡

  • Single-arm, 6 center study of 210 CTO patients evaluating primary end-point of TVF versus performance goal with the SYNERGY BP-DES
  • Low event rates in complex lesions (mean stent length 85.6 mm) and very symptomatic patients

Key Trial Details5

  • 90.5% of patients had pre-PCI IVUS
  • 90% CTO success rate
  • Very complex and symptomatic patients
    • JCTO Score of 2.4
    • Mean stent length 85.6 mm
    • 21% diabetic patients
  • Significant QoL gains at 12-months following successful CTO PCI

TVF at 12-Months

Primary Endpoint: TVF at 12-Months
 

CELTIC Bifurcation Study 9-Month Results6‡

  • Examined outcomes of 170 patients at 8 sites in the UK treated by planned culotte stenting with the SYNERGY BP-DES and the Xience Xpedition™ PP-DES
  • Results showed lower composite primary endpoint, including 0% ST and low restenosis with the SYNERGY BP-DES

Composite Primary Endpoint at 9-Months

Composite Primary Endpoint at 9-Months
‡The safety and effectiveness of the SYNERGY Stent has not been established in multi-vessel disease, CTO lesions or bifurcation lesions.
 
 
Early Healing

Early Healing

Advanced design for optimal healing

Button
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Efficiency

Efficiency

How design impacts economic value

Button
Top